Natalizumab exposure is associated with an increased risk of spontaneous abortion for pregnant women with multiple sclerosis.
Intakes of fats and types of fatty acids may affect disability severity in multiple sclerosis and neuromyelitis optica spectrum disorder.
Patients with multiple sclerosis who were motivated to remain adherent to treatment experienced overall better outcomes, including low relapse rates.
Barriers to using screening tools included lack of time and lack of insurance compensation.
Data obtained from the iConquerMS network highlight areas of quality of life that affect people with relapsing and progressive forms of MS and provide substantial basis for future research.
Vitamin D deficiency is a risk factor for multiple sclerosis.
The association suggests that caffeine consumption may play a protective role against multiple sclerosis-related disability.
Poor medication timing, incorrect doses, medication disorganization, and under- or over-medication are some of the medication adherence issues that can occur in patients with MS and cognitive symptoms.
Obesity-associated lowering of vitamin D levels may not mediate the putative causal relationship between obesity and multiple sclerosis.
Authors describe 2 case reports of MS in the pediatric population after administration of HPV vaccination.
The EFFECT study compared the efficacy of dimethyl fumarate vs other disease-modifying therapies, including fingolimod and glatiramer acetate in patients with relapsing-remitting multiple sclerosis.
A significant unmet need remains for an effective, well-tolerated, and convenient treatment for patients with progressive forms of MS.
The post-hoc analysis compared 6-month confirmed disability progression using patient data from PRISMS-2.
The randomized, double-blind PARADIGM study compared the safety and efficacy of fingolimod and interferon β-1a in teens with relapsing-remitting MS.
Application of technology developed in the gaming and computer control industry offers the opportunity to create new metrics with greater sensitivity and reproducibility.
Study authors emphasize the rebound relapse phenomenon as a potential complication in the safety of fingolimod.
A 55-year-old woman with multiple sclerosis and no history of thyroid disease developed lab abnormalities suggestive of thyrotoxicosis on routine testing.
Relapsing-Remitting Multiple Sclerosis: Maintaining No Evidence of Disease Activity With NatalizumabFebruary 01, 2018
Researchers aimed to determine the proportion of patients with early relapsing-remitting multiple sclerosis treated with natalizumab who achieve no evidence of disease activity at year 2.
Ozanimod decreased both T2 and T1 brain lesions and brain volume loss in patients with relapsing multiple sclerosis.
CRISP will determine the suitability of clozapine and risperidone as a treatment for progressive multiple sclerosis.
Researchers examined patients' disease course and the number of clinical attacks to determine the safety and efficacy of intravenous cladribine.
Rituximab associated with lower drug discontinuation and disease relapse rates in multiple sclerosisJanuary 26, 2018
Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting multiple sclerosis.
Researchers sought to compare 2010 McDonald and MAGNIMS criteria for predicting conversion to MS from clinically isolated syndrome.
Greater disability was associated with lower anti-Müllerian hormone levels in women with MS.
The BRAIN test is limited by its ability to only assess upper limb function.
While both intravenous and oral administrations of methylprednisolone showed similar efficacy, the investigators noted that oral administration may be more tolerable and cost-effective.
The FDA has granted Breakthrough Therapy designation to Fingolimod for treating children with relapsing multiple sclerosis.
The 2017 revision takes aim at better differentiating relapsing-remitting and primary-progressive forms of multiple sclerosis.
Diet quality is associated with disability and symptom severity in multiple sclerosis patients.
Investigators believe this is the largest study on the association between multiple sclerosis and epilepsy.
Neurology Advisor Articles
- FDA Approves Expanded Treatment Window for Clot Retrieval Device in Acute Ischemic Stroke
- Genetic and Imaging Markers in Migraine: Ready for Prime Time?
- Resting Tremor Most Common in Early Parkinson Disease
- Intracerebral Hemorrhage-Related Hospital Mortality Reduced With Prior NOAC Use
- Ethical Considerations in New Coma Research
- Updated Ischemic Stroke Guidelines: Expert Takeaways
- Alternative Genetic Risk Variant for Alzheimer Disease Identified
- Advance Directives for Dementia: Honoring Patient Wishes When You Don't Know What They Are
- Ethical Considerations in New Coma Research
- Poor Sleep Associated With Worse PTSD, Chronic Pain in Youth
- Comparing Reference Points for Deep Brain Stimulation Location in Parkinson Disease
- FDA Approves Clinical Decision Support Tool for Stroke
- US Will Produce Radioisotope for MRI, FDA Says
- Cognitive Decline in Men Linked to Low Serum Sodium
- Solanezumab Every 4 Weeks Does Not Significantly Affect Cognitive Decline in Alzheimer Disease